Running Stocks: Capital Product Partners L.P. (NASDAQ:CPLP), ZIOPHARM Oncology (NASDAQ:ZIOP), Trillium Therapeutics (NASDAQ:TRIL)

Cobalt International Energy, Inc. (NYSE:CIE) shares moved up 0.67% in last trading session and ended the day at $7.55. CIE has a return on assets of -11.40%. Cobalt International Energy, Inc. (NYSE:CIE) quarterly performance is -16.11%.

James Hardie Industries plc (NYSE:JHX) ended the last trading day at $12.70. Company weekly volatility is calculated as 2.10% and price to cash ratio as 61.33. James Hardie Industries plc (NYSE:JHX) showed a weekly performance of 6.01%.

Zacks cut shares of James Hardie Industries plc (NYSE:JHX) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday morning, Market Beat reports.

On 06 October, Capital Product Partners L.P. (NASDAQ:CPLP) shares decreased -1.29% and was closed at $6.88. CPLP EPS growth in last 5 year was -23.10%. Capital Product Partners L.P. (NASDAQ:CPLP) year to date (YTD) performance is -6.62%.

Capital Product Partners L.P. (NASDAQ: CPLP) announced the successful acquisition of the M/V ‘CMA CGM Uruguay ‘. Pursuant to the Master Vessel Acquisition Agreement we entered into on July 24th, 2014, the Partnership took delivery on September 21st 2015 of the M/V ‘CMA CGM Uruguay ‘ (115,145 dwt / 9,288 TEU, Eco-Flex, Wide Beam Containership built 2015, Daewoo-Mangalia Heavy Industries S.Α.), the fourth of five vessels (the ‘Dropdown Vessels’) that we have agreed to acquire from our sponsor, Capital Maritime & Trading Corp. (‘Capital Maritime’).

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares decreased -1.15% in last trading session and ended the day at $10.34. ZIOP has a return on assets of -124.50%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) quarterly performance is -2.91%.

On September 28, 2015, ZIOPHARM Oncology, Inc., (NASDAQ:ZIOP) or the Company, entered into an Exclusive Channel Collaboration Agreement, or the Agreement, with Intrexon Corporation, or Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo expression of effectors to research, develop and commercialize products for use in the treatment or prevention of graft-versus-host disease, or GvHD. The exclusive collaboration, or the GvHD Program, will focus on the pursuit of the following engineered cell therapy strategies, used either separately or in combination, for the targeted treatment of GvHD.

Trillium Therapeutics Inc. (NASDAQ:TRIL) caters to the Healthcare space. Its weekly performance is 6.00%. On the last day of trading company shares ended up at $13.43. Trillium Therapeutics Inc. (NASDAQ:TRIL) distance from 50-day simple moving average (SMA50) is -21.40%.

On 30 September, Trillium Therapeutics Inc. (NASDAQ:TRIL) announced that it has completed the manufacture of clinical-grade drug product, concluded a comprehensive IND-enabling non-clinical safety assessment program, and has proposed a design for its first-in-human clinical trial with TTI-621 (SIRPaFc).